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Abstract
Emerging viruses are usually endemic to tropical and sub-tropical regions of the world, but increased global travel, climate
change and changes in lifestyle are believed to contribute to the spread of these viruses into new regions. Many of these
viruses cause similar disease symptoms as other emerging viruses or common infections, making these unexpected
pathogens difficult to diagnose. Broad-spectrum pathogen detection microarrays containing probes for all sequenced
viruses and bacteria can provide rapid identification of viruses, guiding decisions about treatment and appropriate case
management. We report a modified Whole Transcriptome Amplification (WTA) method that increases unbiased
amplification, particular of RNA viruses. Using this modified WTA method, we tested the specificity and sensitivity of the
Lawrence Livermore Microbial Detection Array (LLMDA) against a wide range of emerging viruses present in both non-
clinical and clinical samples using two different microarray data analysis methods.
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Introduction
Emerging viruses may be defined as viruses that are newly
discovered or have the potential to increase in incidence or
geographical range. Some important emerging viruses cause
severe acute syndromes such as viral haemorrhagic fevers or
encephalitides. They are endemic to tropical and sub-tropical
regions. The majority are RNA viruses, from the Arenaviridae,
Bunyaviridae, Filoviridae, Flaviviridae and Togaviridae virus families, but
some are from DNA virus families such as Poxviridae. Their survival
often depends on a vertebrate or arthropod host (non-human
primates, bats, birds, rodents, ticks, sandflies or mosquitoes) [1–4].
They are usually restricted to geographical areas where the host
species lives. Human cases occur through zoonosis, often resulting
in life-threatening diseases with high mortality rates [3]. Knowl-
edge of some of these viruses is limited, and originates exclusively
from case reports and animal models. Some of them were first
described during surveillance of veterinary diseases, e.g. Usutu
virus, and only later became implicated in human clinical cases
[5,6].
Due to increased global travel, lifestyle changes and climate
change, the risk of importing rare, exotic and emerging diseases to
Europe has increased [3]. Some areas in Europe already maintain
environmental conditions favourable to these pathogens, e.g.
hantavirus [7], Crimean-Congo haemorrhagic fever virus
(CCHFV) [8] and West Nile virus (WNV) [9]. Travellers visiting
endemic areas are a potential source for spreading these diseases,
which manifest as febrile illness coinciding with the peak of viral
shedding and consequent risk of transmission. Disease symptoms
may be nonspecific and similar to those of other common diseases,
making them clinically difficult to recognize and diagnose [10].
There is a demand for rapid and accurate identification of the
virus to initiate specific treatment, if available, as well as
appropriate case management such as isolation and contact
tracking [10,11]. The use of real-time PCR has been critical for
case management and epidemiological investigation, complement-
ing serological diagnostic tools [12]. However, a PCR assay can
only detect the presence of a specific virus, or a small group of
viruses, and real-time PCR multiplexing is limited by overlapping
fluorophore emission spectra and available detection channels in
real-time PCR cyclers [13].
Several metagenomic approaches, such as microarrays [14–16],
resequencing microarrays [17] and next generation sequencing
[18], have been shown to be promising new tools for broad-
spectrum diagnosis of common viral infections [19–21], arboviral
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diseases [22] and tropical febrile illnesses [23,24]. These methods
all have the ability to simultaneously test for the presence of
thousands of viruses in a single assay and thereby remove the need
for a specific clinical hypothesis regarding a suspected pathogen.
The Lawrence Livermore Microbial Detection Array (LLMDA)
is a high density oligonucleotide microarray that contains probes
for all sequenced viruses and bacteria [14]. It has been used to
detect a wide range of viruses in both clinical samples [19,25] and
vaccine products [26]. In this study we report a modified Whole
Transcriptome Amplification (WTA) protocol that increases the
unbiased amplification of viruses, especially RNA viruses. Using
this method we show that the version 2 of the LLMDA
(LLMDAv2) is sensitive and specific to a wide range of emerging
viruses and successfully identifies emerging virus present in clinical
samples. In addition we compare the simpler SSI-developed data
analysis method with the more sophisticated CLiMax software
developed especially for LLMDA arrays.
Materials and Methods
Ethics Statement
Exemption for review by the ethical committee system and
informed consent was given by the Committee on Biomedical
Research Ethics-Capital region in accordance with Danish law on
assay development projects.
Data Availability Statement
All authors comply with the data availability policy.
Virus from Non-clinical Samples
Within the European Network for Diagnostics of Imported
Viral Diseases (ENIVD) we gathered a wide range of emerging
viruses, as inactivated culture supernatants or as purified viral
DNA or RNA (Table 1). Viruses were inactivated by heat and/or
gamma-irradiation, or by suspension in an RNA-extraction
reagent (TRIzol, Life Technologies; TriFast, Peqlab; AVL buffer,
Qiagen) [27]. The majority of viruses were grown in Vero E6 cell-
cultures (kidney epithelial cell line derived from African green
gonkey) (ATCC CRL-1586), but poliovirus (PV) was grown in
L20B cells (a murine recombinant cell line) [28]. We also used six
control samples from the QCMD EQA programme for 2010 and
2013 (WNV10-01, WNV10-07, WNV13-01, WNV13-10,
WNV13-11 and DENV13-01). The WNV13-01 sample contained
West Nile virus (WNV) at a concentration of 1.06107 copies/ml
and the DENV13-01 sample contained Dengue virus (DENV)
type 1 at a concentration of 1.06106 copies/ml. The WNV10-01
and WNV13-10 samples contained a mixture of flaviviruses
(DENV type 1, 2 and 4, and Japanese encephalitis virus (JEV)).
The WNV10-07 and WNV13-11 samples contained a mixture of
DENV type 3, tick-borne encephalitis virus (TBEV) and yellow
fever virus (YFV), each at a concentration of 1.06106 copies/ml.
Virus from Clinical Samples
We used clinical samples received for routine diagnostic analysis
at Statens Serum Institut (SSI), Copenhagen, Denmark (Danish
National reference laboratory (ISO 17025; 2005)), from the CCH
Fever Project bio-bank at the Swedish Institute for Communicable
Disease Control (Sweden), and from the Department of Micro-
biology, Aristotle University of Thessaloniki (Greece). The samples
were (Table 2): i) One parapoxvirus-positive skin lesion (blister)
sample from the hands of a shepherd; ii) One Chikungunya virus-
positive serum sample from a traveller hospitalized for Dengue-like
symptoms (high fever, joint pain, rash) after visiting Thailand; iii)
Eight DENV-positive serum samples from travellers experiencing
mosquito bites in the jungle of Thailand, iv) One CCHFV-positive
serum sample (from the CCH Fever program); v) One sandfly
fever Toscana virus-positive cerebrospinal fluid (CSF) sample from
a traveller hospitalized with meningitis after visiting Toscana,
Italy; vi) Six WNV-positive urine samples from patients hospital-
ized with West Nile fever (two of them with encephalitis). In
addition, we used six hepatitis C virus (HCV)-positive serum
samples and five HCV-positive plasma samples. One of the HCV-
positive serum samples had a known viral concentration (1.26106
IU/ml) determined by standardisation against the WHO control.
As negative controls we used virus-negative clinical samples (urine,
CSF and serum).
Purification of Samples
As previously described [19] we centrifuged 230 ml of sample at
17,000 g for 10 min, filtered the supernatant through a 0.22 mm
Spin-X spin filter (Costar) and treated it with DNase (Invitrogen or
New England Biolabs) for 30 min-1K h. The viral nucleic acid
(NA) was extracted using the PureLink Viral RNA/DNA kit
(Invitrogen), without the addition of carrier RNA. All samples
were treated with this protocol with the exception of the QCMD
panel samples, CSF, urine, and plasma samples, which were not
DNase treated. Virus-positive supernatants suspended in RNA-
extraction reagent were purified according to the manufacturer’s
instructions (TRIzol, Life Technologies; TriFast, Peqlab; AVL
buffer, Qiagen). The resulting RNA was further purified using the
QIAamp RNA viral Mini kit (Qiagen). The extracted viral NA was
eluted with 30–50 ml DNase/RNase-free water, and stored at 2
20uC or immediately used.
Reverse Transcription
Reverse transcription (RT) on purified viral RNA was
performed with three different methods: i) The P-N6/SSIII
method, which uses the Superscript III Reverse Transcription kit
(Invitrogen), combined with 59-phosphorylated random hexamers
(P-N6) (Eurofins MWG Operon). Briefly, 11–12 ml viral RNA was
mixed with 1 ml 10 mM dNTP mix and 1 ml 250 ng/ml P-N6,
incubated at 85uC for 5 min, and cooled on ice. Next, 4 ml 5x first
strand buffer, 1 ml 0.1 M DTT, 1 ml RNaseOUT (40 U/ml)
(optional) and 1 ml Superscript III RT enzyme (200 U/ml) was
added, and the sample mixed and incubated at 25uC for 10 min,
42uC for 60 min and 95uC for 5 min. ii) The RT-reaction
included in the WTA kit (Qiagen), which uses T-Script reverse
transcriptase combined with random and oligo-dT primers. RT
was performed according to the manufacturer’s instructions. iii)
The VILO method, which uses a cDNA Synthesis kit (Invitrogen)
containing Superscript III reverse transcriptase combined with
random primers. The method was performed as previously
described [19,29]. The samples were stored at 220uC or
immediately used.
Whole Transcriptome Amplification
For viral RNA amplification we used the WTA method [29]
with the QuantiTect WTA kit (Qiagen), except for the reverse
transcription step that was replaced by one of the three RT
methods described above. We also modified the protocol by
performing amplification at 30uC for 2–8 h. We purified Repli-g
amplified DNA according to the supplementary protocol, using
the QIAamp DNA Mini Kit (Qiagen), and validated its purity and
concentration using a NanoDrop spectrophotometer (Thermo
Scientific). The DNA was stored at 280uC or immediately used.
To avoid contamination between samples, we adopted precautions
normally used during routine viral diagnostic PCR analysis at SSI,
Diagnostic Microarray for Emerging Viruses
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where extraction, amplification and analyses are physically
separated and negative samples are included in all steps.
Quantification and Confirmation by Real-time PCR
The technique used for routine diagnostic virus analysis at SSI is
quality-assured real-time PCR (ISO 17025; 2005, SSI). To
confirm presence of virus in the samples and quantify the virus
before and after WTA, we performed virus-specific real-time
PCR. We used in-house assays for DENV, WNV, orthopoxvirus,
parapoxvirus, Usutu virus, Hantaan virus, Toscana virus, BK virus
(BKV) and rotavirus A; and previously published assays for JC
virus (JCV) [30], cowpox and monkeypox viruses [31], Chikun-
gunya virus [32], Eastern equine encephalitis virus (EEEV) [33],
JEV [34], TBEV [35], YFV [36], Lassa virus and CCHFV [37],
Dobrava-Belgrade virus (DOBV) [38], Puumala virus [39], Rift
Valley fever virus (RVFV) [36] and Marburg virus [40]. PCR was
performed using an Mx3005P (Stratagene) thermal cycler. We
calculated the fold difference in concentration from the DCt
obtained from real-time PCR before and after WTA, combined
with dilution factors. Here we made the assumption that 1 cycle
change in Ct-value was equivalent to a doubling of target DNA.
We estimated the sample concentrations of the HCV-positive,
DENV-positive and WNV-positive clinical samples by performing
a series of 10-fold dilutions of the HCV-positive serum sample
(1.26106 IU/ml), the DENV13-01 QCMD sample (1.06106
copies/ml) and the WNV13-01 QCMD sample (1.06107 copies/
ml), under the assumption that no viral NA was lost during
purification.
Microarray Analysis
We analysed samples with the LLMDAv2 microarray, devel-
oped at the Lawrence Livermore National Laboratory (LLNL),
USA and described elsewhere [14,19,41]. The LLMDAv2
contains 388,000 oligonucleotides probes designed from all
sequenced viruses and bacteria [14]. Labelling and microarray
hybridization was performed according to manufacturer protocols
(Gene expression analysis, Roche NimbleGen) with the exception
that 8 mg, instead of 2 mg, of labelled material was used for
hybridization. Microarray data was analysed using a simple Excel-
based data analysis method developed at SSI (SSI analysis) as
described previously [19]. Since the SSI analysis is not optimized
for bacteria, any bacterial hits were excluded from the results.
Non-human, non-zoonotic pathogens were also excluded since
they are assumed to be clinically irrelevant in a diagnostic setting.
Additional data analyses were performed on the samples using the
CLiMax software developed at LLNL and described elsewhere
[14,41].
Microarray data were submitted to the Gene Expression
Omnibus (GEO) database http://ncbi.nlm.nih.gov/geo/with the
accession number GSE55576. All microarray data used in this
study are MIAME compliant.
Results
A Modified WTA Protocol Using 59-Phosphorylated
Random Primers for cDNA Synthesis
To enable successful microarray identification of virus in clinical
samples, we have previously used the Phi29 polymerase-based
WTA method (Qiagen) [19,29]. The WTA protocol includes three
sequential reactions: a reverse transcription reaction to generate
cDNA, ligation of cDNA fragments into large linear chains, and
amplification by the Phi29 polymerase [29]. To assure an efficient
ligation, we replaced the included RT reaction with Superscript
III and 59-phosphorylated random hexamers (P-N6) hereafter
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called P-N6/SSIII. This was done in order to phosphorylate the
59-end of the cDNA fragments so that new phosphodiester bonds
could be formed during the ligation step [42,43]. We compared
this method to the manufacturers RT reaction (T-Script using
random and oligo-dT primers) and to RT using Superscript VILO
cDNA kit [19,29]. Prior to RT and amplification, samples were
pre-treated according to a previously described protocol [19]. The
different RT protocols were tested in parallel on 10-fold serial
dilutions of an HCV-positive serum sample (1.26106 IU/ml)
(Figure 1A), on two supernatants containing the hantaviruses
Puumala virus and DOBV, respectively (Figure 1B), and on 10
HCV-positive clinical samples with varying viral concentrations
(Figure 1C–1D). For all samples tested, whole transcriptome (WT)
amplification of cDNA generated by P-N6/SSIII was more
efficient than VILO or T-Script. Therefore, the P-N6/SSIII
RT-reaction was used for all further WT amplifications.
WT Amplification of Emerging Virus in Non-clinical
Samples
WT amplification using the P-N6/SSIII RT-method was tested
for its ability to amplify emerging viruses. Due to difficulty in
getting access to clinical samples positive for a diverse set of
emerging viruses, we initially tested the method on a wide range of
virus-positive cell culture supernatants (SN), purified viral NA or
QCMD panel samples (Table S1). The WT amplification was
analysed using virus specific real-time PCRs before and after
amplification (Table S1 and Figure 2). For all samples tested,
amplification of the emerging virus was observed (Figure 2A). For
EEEV (Alphavirus), Usutu virus (Flavivirus), WNV (Flavivirus), PV
(Enterovirus), Hantaan virus (Hantavirus), RVFV (Phlebovirus)
and Toscana virus (Phlebovirus) the amplification was relatively
small with a fold increase between 25–500 (Table S1 and
Figure 2A). However, for other samples much larger fold increases
were observed, such as JEV (Flavivirus) with a fold increase of
1.56106, DOBV (Hantavirus) with a fold increase of 4.56106 and
Puumala virus (Hantavirus) with a fold increase of 1.46104 (Table
S1 and Figure 2A). When we examined the relationship between
amplification (fold increase) and viral content (Ct-values before
WT amplification) (Figure 2B), we observed a significant correlation
between WT amplification and viral content. Samples containing a
high viral content were amplified to a lesser extent than samples
containing a lower viral content, which could reflect that for samples
with a high concentration of NA, primers and nucleotides are
depleted quickly, resulting in a lower WT amplification.
Table 2. Microarray results on non-clinical samples using two different data analysis methods.
Group* Genus Virus Sample Detected virus SSI analysis Detected virus CliMax analysis
dsDNA Orthopoxvirus Cowpox pur. DNA Cowpox virus, Variola virus,
Monkeypox virus, Vaccinia virus, HERV
Cowpox virus, Variola minor virus‘, BEV,
HERV
Monkeypox Pur. DNA Monkeypox virus, Variola virus,
Cowpox virus, Vaccinia virus, HERV
Monkeypox virus, Variola minor virus‘,
BEV, HERV
(+) ssRNA Alphavirus EEEV SN EEEV, HERV EEEV, BEV, HERV, SRV-1‘
Flavivirus Usutu pur. RNA Usutu virus, HERV, JEV Usutu virus, BEV, HERV
WNV pur. RNA WNV, HERV WNV, BEV, HERV
JEV, DENV-2, DENV-1,
DENV-4
WNV10-01 JEV, DENV-2, DENV-1, DENV-4 JEV, DENV-2, DENV-1, DENV-4,
DENV-3, BVDV-1‘, RV-A, PRV-C
TBE, DENV-3, YF WNV10-07 TBEV, DENV-3, YFV, DENV-1,
DENV-2, OHFV, HERV
TBEV, DENV-3, YFV, DENV-2, SV5,
RV-A, PRV-C
Enterovirus PV-1, PV-2 SN PV-1, PV-2, PV-3 PV-1, PV-2, MuLV, SV40, MDEV, MMTV
(2) ssRNA Arenavirus Lassa SN Lassa virus Lassa virus
Hantavirus DOBV SN DOBV DOBV
Hantaan SN Hantaan virus Hantaan virus, MRV-3, MRV-1, MuLV
Puumala SN Puumala virus, HERV Puumala virus, BEV, HERV, BVDV-1‘
Seoul SN Seoul virus, HERV Seoul virus
Sin Nombre SN Sin Nombrevirus, HERV Sin Nombre virus, BEV, HERV, SRV-1
Nairovirus CCHF SN CCHFV, HERV CCHFV, HERV, BEV
Phlebovirus RVF SN RVFV, HERV RVFV, CCHFV, SV5, BEV, HERV
Naples SN Naples virus Naples virus, BVDV-1
Sicilian SN Sicilian virus Sicilian virus
Toscana SN Toscana virus, HERV Toscana virus, BEV, HERV, SRV-1
Ebolavirus Ebola Zaire SN Ebola Zaire virus, HERV Ebola Zaire virus, HERV, BEV, SRV-1
Marburgvirus Marburg SN Marburg virus, HERV Marburg virus, HERV, BEV, RVFV‘
NOTE. EEEV, Eastern equine encephalitis virus; WNV, West Nile virus; CCHFV, Crimean-Congo haemorrhagic fever virus; RVFV, Rift-Valley fever virus; TBEV, Tick borne
encephalitis virus; OHFV, Omsk hemoratic fever virus; YFV, yellow fever virus; PV, poliovirus; HERV, human endogenous retrovirus; JEV, Japanese encephalitis virus;
DENV, Dengue virus; DOBV, Dobrava-Belgrade virus; RV-A, rotavirus A; PRV-C, porcine rotavirus C; BEV, baboon endogenous virus; SRV-1, simian retrovirus 1; MuLV,
murine leukemia virus; SV40, simian virus 40; MDEV, mus dunni endogeneous virus; MMTV, mouse mammary tumour virus; MRV, mammalian orthoreovirus; BVDV,
bovine viral diarrhea virus; SV5, simian virus 5; pur. DNA, purified DNA; SN, cell culture supernatant; pur. RNA, purified RNA; WNV10-01, sample from QCMD EQA WNV
panel 10-01; WNV10-07, sample from QCMD EQA WNV panel 10-07 Bold represents correctly identified virus.
‘Viruses with fragmented alignment plots.
*Viruses are grouped based on nucleic acid content, according to the Baltimore Classification.
doi:10.1371/journal.pone.0100813.t002
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To investigate whether the presence of several viruses in a
sample would interfere with WT amplification, we tested two
QCMD panels of samples (WNV10-01 and -07) containing
mixtures of four and three different flaviviruses, respectively, each
at a concentration of 1.06106 copies/ml (Table S1 and Figure 2A).
All seven flaviviruses were WT amplified; however DENV-1 was
amplified to a lower degree than to the other DENV subtypes or
flaviviruses (Figure 2A). This most likely reflect a difference in the
sensitivity of the Dengue subtype-specific primers used to analyse
the WT amplification rather than virus subtype-specific variation
in the WT amplification. In summary, the modified WT
amplification method was able to amplify emerging viruses in 21
different non-clinical samples.
Microarray Detection Range
To test the sensitivity of the previously described LLMDA
microarray [14,19,26] for RNA viruses, we performed microarray
analysis on a 10-fold dilution series of a HCV-positive serum
sample (1.26106 IU/ml), a RVFV-positive supernatant (3.36106
copies/ml), a WNV-positive QCMD panel sample (WNV13-01)
(1.26107 copies/ml), a DENV-positive QCMD panel sample
(DENV13-01) (1.06106 copies/ml) and two QCMD panel
samples (WNV13-10 and WNV13-11) containing mixtures of
JEV, DENV-1, DENV-2, DENV-4 and YFV, DENV-3, TBEV
respectively (1.06106 copies/ml) (Table 1). Dilutions ranging from
106 to 102 copies/ml were WT amplified, labelled and hybridised
to the LLMDAv2 microarray. Microarray analysis was performed
using the SSI [19] and CLiMax data analysis methods [14,41]
(data not shown).
For the HCV, RVFV and WNV samples, dilutions of 106 to 103
copies/ml yielded sufficient viral material for successful identifi-
cation by the LLMDAv2, while dilutions of 102 copies/ml were
not detected by the microarray (Table 1). Dilutions of 102 copies/
ml will theoretically result in an input of 24 copies to the RT-
reaction and 12 copies to the WTA-reaction. Analyses of the viral
concentrations after WT amplification of the non-detectable 102
copies/ml dilutions showed that RVFV, HCV and WNV were
amplified to 1.76105, 4.36105 and 4.46105 copies/ml, respec-
tively (Table 1).
The detection limit for DENV, JEV and TBEV was 104 copies/
ml (Table 1) and the detection limit for YFV was higher (105
copies/ml) than the rest of the flaviviruses analysed. The WNV13-
11 sample was documented as containing YFV, DENV-3 and
TBEV, each at 1.06106 copies/ml; however, analysis of the Ct-
values of YFV and TBEV before amplification showed a higher
value for YFV (Ct = 27) compared to TBEV (Ct = 23) (Table 1),
which could indicate a lower viral content of YFV in the WNV13-
11 sample than was documented. Analysis of the viral concentra-
tion after WT amplification of the non-detectable 103 copies/ml
dilutions showed that DENV, JEV and TBEV were amplified to
3.16105, 1.06104 and 2.16104 copies/ml, respectively (Table 1).
From this we conclude that at least 103 copies/ml is needed for a
successful amplification with the modified WTA method and at
least 105 copies/ml is needed after WT amplification in order to
Figure 1. Improved WT amplification when using 59-phosphorylated random hexamers in RT-reaction. Comparison of three different
RT-reactions in the Whole Transcriptome Amplification (WTA) protocol. Purified viral RNA was amplified by WTA using VILO, T-Script or P-N6/SSIII RT-
reaction. Virus-specific real-time PCR was performed before and after the amplification step, and fold increase was calculated using DCt-values and
dilution factors for each sample tested. (A) WTA-protocols tested with a 10-fold serial dilution of an HCV-positive serum sample with known
concentration. (B) WTA-protocols tested with two different virus-positive cell culture supernatants, Puumala virus and Dobrava-Belgrade virus (DOBV),
respectively. (C) WTA-protocols tested with five HCV-positive serum samples with estimated concentration (IU/ml). (D) WTA-protocols tested with five
HCV-positive plasma samples with estimated concentration (IU/ml).
doi:10.1371/journal.pone.0100813.g001
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reliably identify viruses with the LLMDAv2. This concentration is
equivalent to 0.17 femtomolar, demonstrating exquisite sensitivity
of the LLMDAv2 platform.
Microarray Detection of Emerging Virus in Non-clinical
Samples
The LLMDA microarray [14,19,26] was tested for its ability to
correctly identify a wide range of virus-positive cell culture
supernatants (SN), purified viral NA or QCMD panel samples
containing emerging viruses (Table 2). The WT amplified samples
previously described (Table S1) were labelled and hybridised to the
LLMDAv2 microarray. Microarray analysis was performed using
the SSI [19] and CLiMax data analysis methods [14,41].
In all 21 samples analysed, both methods identified the correct
virus (Table 2). In more than half of the samples, human
endogenous retroviruses (HERV) were also found (Table 2), con-
sistent with the presence of human host DNA. The CLiMax method
identified additional retroviruses such as baboon endogenous virus
Figure 2. Modified WT amplification of non-clinical samples containing emerging virus. Purified viral RNA from a wide range of virus-
positive cell culture supernatants (SN) or QCMD panel samples was amplified by WTA using the P-N6/SSIII RT-reaction. Virus-specific real-time PCR
was performed before and after the amplification step, and fold increase was calculated using DCt-values and dilution factors for each sample tested.
(A) Fold increase of WT-amplified emerging viruses belonging to different virus genera. The two QCMD panel samples (WNV10-01 and WNV10-07)
containing mixtures of different flaviviruses are highlighted. (B) The correlation between fold increase in WT amplification and viral sample content
(Ct before WT amplification).
doi:10.1371/journal.pone.0100813.g002
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Figure 3. CLiMax analysis detects Puumala virus in a non-clinical sample. The results of microarray analyses of WT-amplified viral DNA-
samples, using CLiMax analysis. (A) Log-odds scores for a Puumala virus-positive sample. The lighter and darker-coloured portions of the bars
represent the unconditional and conditional log-odds scores, respectively. The conditional log-odds scores shows the contribution from a target that
cannot be explained by another, more likely target above it, while the unconditional score illustrates that some very similar targets share a number of
probes. (B) Target sequence-probe alignment plots for segment L of the Puumala virus genome and for BVDV-1, showing probe intensity vs probe
position in the viral genome. Plot symbol and color indicates positive (.99th percentile), negative (,95th percentile), or equivocal hybridisation
signals; hollow symbols indicate probes found to hybridise non-specifically. The pattern seen for BVDV-1, in which positive probes are restricted to a
few narrow genome regions, is a typical cross-hybridisation result.
doi:10.1371/journal.pone.0100813.g003
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(BEV), simian retrovirus 1 (SRV-1), Mus dunni endogeneous virus
(MDEV), murine leukemia virus (MuLV) and mouse mammary
tumour virus (MMTV). These additional viruses were not identified
by the SSI method because non-human, non-zoonotic pathogens
were considered clinically irrelevant and excluded in the SSI data
analysis.
For four of the samples (cowpox virus, monkeypox virus, PV-1/
PV-2 and Usutu virus), the SSI method had difficulties in
distinguishing between different genus-members and subtypes. In
the Usutu virus sample (Flavivirus), the SSI method identified both
Usutu virus and JEV, another Flavivirus species, as being present,
while the CliMax analysis correctly identified Usutu virus only. In
the PV sample, the CLiMax analysis correctly identified PV-1 and
PV-2, while the SSI analysis made an additional false-positive
detection of PV subtype 3 (Table 2). In the samples of cowpox
virus and monkeypox virus, both methods identified additional
members of the Orthopoxviridae family as present. The SSI analysis
identified both samples as mixtures of cowpox, monkeypox,
vaccinia and variola viruses, while the CliMax analysis identified
the correct cowpox or monkeypox virus together with the variola
minor virus (Table 2), which belongs to the same genus. Detailed
examination of the probes with positive signals (greater than the
99th percentile of the negative control intensities) showed that all
such probes with alignments to the variola minor virus genome
had strong matches in the cowpox and monkeypox genomes; so
that the identification of variola minor virus in the CliMax analysis
in these samples is most likely due to cross-hybridization of these
probes.
For five samples (Hantaan virus, Puumala virus, RVFV, Naples
virus and Marburg virus) the CLiMax analysis identified
additional viruses that were not observed using the SSI analysis
(Table 2). To better understand the source of these additional
predictions, we used the CliMax software to generate sequence-
probe alignment plots, where the intensity of each probe is plotted
against its alignment position in the viral genome. These plots
clarify whether identification of a virus is based on presence of the
whole genome or may be due to cross-hybridization from probes
matching sub-regions of other genomes present in the sample. For
example, the sequence-probe alignment plots for the Puumala
virus sample show the positive probes to be uniformly distributed
across all three Puumala virus genome segments, indicating the
presence of the whole viral genome (Figure 3B, top). Probe hits for
the bovine viral diarrhea virus 1 (BVDV-1) genome show a
different pattern, landing in only a narrow region suggesting
nonspecific- or cross-hybridisation (Figure 3B, bottom). We refer
to this pattern as a fragmented alignment plot.
We observed a similar fragmented alignment pattern for RVFV
segment S in the Marburg sample, indicating non-specific cross-
hybridisation (data not shown). In contrast, we obtained uniform
positive probe distributions for mammalian orthoreovirus 1 and 3
(MRV) genomes in the Hantaan virus sample, for CCHFV and
Simian virus 5 (SV5) genomes in the RVFV sample, and for
BVDV-1 in the Naples virus sample, indicating that these
complete viral genomes were truly present (data not shown).
CCHFV specific PCR could not confirm the presence of CCHFV
in the RVFV sample (data not shown). The other additional
findings were all considered clinically irrelevant and therefore not
further investigated by PCR.
The presence of several viruses in a sample did not interfere
with identification, as can be seen by the microarray analysis of the
two panels of samples (WNV10-01 and -07) containing mixtures of
different flaviviruses (Table 2). Microarray analysis correctly
identified all four viruses present in WNV10-01 and all three
viruses present in WNV10-07 (Table 2). However, the individual
DENV subtypes were difficult to distinguish completely. In the
WNV10-10 sample the CLiMax analysis identified DENV type 3,
and in the WNV10-07 sample both analysis methods detected
DENV type 1 and 2. These extra DENV findings were later
confirmed as false-positives by Dengue subtype-specific PCR (data
not shown). In addition, the SSI analysis of the WNV10-07 sample
identified Omsk haemorrhagic fever virus (OHFV), which also
belongs to the Flavivirus genus [44]. This finding was not observed
using the CLiMax analysis and hence not checked by PCR. The
CLiMax analysis also found HERV, rotavirus A and porcine
rotavirus C in both samples as well as BVDV-1 in WNV10-01 and
SV5 in WNV10-07. The presence of rotavirus A was confirmed by
rotavirus A-specific PCR (data not shown). BVDV, SV5 and
porcine rotavirus C were considered clinically irrelevant and
therefore not confirmed by PCR.
In summary, the LLMDAv2 correctly identified single and
multiple viruses present in non-clinical samples with a very low
level of false positive signals. The CLiMax analysis method
identified every virus present in the samples whereas the simpler
SSI analysis method only identified clinically relevant human
pathogens.
Microarray Detection of Emerging Viruses in Clinical
Samples
We tested the LLMDAv2 microarray on 18 clinical samples
previously identified as positive by real-time PCR for emerging
viruses. The correct virus was identified in 17 samples using both
the SSI (Table 3) and CLiMax analyses (data not shown). The
sample identified only as a parapoxvirus was determined to be Orf
virus, a member of the Parapoxvirus genus. Seven of the eight
DENV-positive samples were clearly determined by the micro-
array analysis to be positive for DENV type 2, DENV type 1 or
DENV type 3. DENV type 4 was not identified in any of the
clinical samples. Additional DENV subtypes were detected in four
of the samples, but at very low probe signal intensities compared to
the correct DENV subtype probe signal (Figure 4A+4B). These
were confirmed as negative by Dengue subtype-specific PCR (data
not shown). One DENV-positive sample was also positive for
hepatitis GB virus C (GBV-C). One DENV-positive sample was
not identified by the microarray. Six urine samples were positive
for WNV and two of these samples were identified as having
additional viruses (Table 3). One WNV sample was also positive
for the polyomaviruses JCV and BKV (Figure 4C), which later
were confirmed as present by PCR (data not shown). Another
WNV sample was positive for JEV (Figure 4D), but this finding
could not be confirmed by PCR (data not shown). In addition, the
microarray detected HERV in almost all samples, consistent with
the presence of human DNA, and the common Torque Teno virus
(TTV) [19,23,45] in the CCHFV and two DENV samples. Virus-
negative urine, CSF and serum were also analysed and confirmed
to be negative for virus (Table 3), except for HERV found in the
CSF sample. In summary, the LLMDAv2 correctly identified
emerging viruses present in 17 of the 18 clinical samples analysed.
The only sample not identified was a DENV-positive sample, in
which the viral concentration was determined to be below the
detection limit, as described below.
To assess viral concentration in clinical samples, we performed
specific real-time PCR before and after WT amplification. We
estimated the viral concentration of 6 WNV-positive urine samples
and 6 DENV-positive serum samples by comparison to PCR
results for the series of 10-fold dilutions of the QCMD panel WNV
and DENV samples (Table 2 and Table 3). The WNV-positive
urine samples were determined to have concentrations between
3.76104 and 4.96105 copies/ml before WTA and concentrations
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between 3.06105 and 2.86107 copies/ml after WT amplification
(Table 3). These samples all had concentrations above the
detection limit (103 copies/ml) determined for dilutions of the
WNV-positive QCMD sample (WNV13-01) (Table 1). Analysis of
the WT amplification showed that WNV from urine samples was
not amplified as efficiently as WNV from the QCMD sample
(Table 1 and Table 3), however the concentration after WTA was
still above 105 copies/ml and hence detectable by the LLMDAv2.
The DENV-positive serum samples were determined to have
concentrations between 1.16104 and 1.86107 copies/ml before
WT amplification and between 1.46105 and 2.561012 copies/ml
after WTA (Table 3). The DENV-positive sample which was not
detected by the microarray had an estimated concentration of
1.16104 copies/ml, which was near the pre-amplification detec-
tion limit seen for dilutions of the QCMD DENV sample (104
copies/ml) (Table 1 and Table 3); and a concentration after WTA
of 1.46105 copies/ml, which is near the post-WTA limit of
detection (105 copies/ml). This sample was also near the limit of
detection with real-time PCR, with a Ct value of 37 before
amplification. In summary, 11 out of 12 clinical samples analysed
had viral concentrations above the detection limit of the
LLMDAv2.
Discussion
The disease symptoms for emerging viruses are often similar to
those of other more common viruses, posing a diagnostic challenge
to clinicians unfamiliar with the novel organism. In the case of
emerging viruses it is crucial for patient treatment and for
containment of a potential epidemic to quickly identify the correct
virus. We demonstrate the ability of the LLMDAv2 array
combined with a modified WTA protocol to correctly identify
29 different emerging viruses in both clinical and non-clinical
samples. Previously we have also shown that LLMDAv2 can
detect a broad range of common viruses in clinical samples [19].
We show a sensitivity of 103–104 copies/ml for different emerging
RNA viruses, which is in the range of clinical relevance, but not as
sensitive as specific real-time PCR. However, the use of PCR
requires a specific hypothesis as to the causative agent, which is not
the case with the LLMDA array. We use a modified random WTA
method to amplify the RNA virus and show that least 105 copies/
ml of amplified material is needed in order to have a successful
identification by the LLMDAv2. This is equivalent to the recently
published data that show detection of 105 copies of vaccinia virus
DNA without any amplification prior to hybridization to the
4x72K version of the LLMDA [46].
The samples used in this study to measure sensitivity were all
dilutions of viral samples or supernatants and do not represent
clinical samples containing low viral concentrations. Therefore,
further experiments to investigate clinical sensitivity are warrant-
ed. Previous reports have shown high clinical sensitivity (86–97%)
and specificity (98–99%) of another microarray, the Virochip [15],
when it was applied to samples from different respiratory virus
infections that were confirmed by specific PCR [20,21]. In our
study, we correctly identified emerging viruses in 17 out of 18
clinical samples that were positive by specific PCR, corresponding
to a clinical sensitivity of 94%. However, this study must be
considered preliminary due to its small size. We are currently
comparing the LLMDAv2 against standard diagnostic real-time
PCR tests for a wide range of viruses and clinical sample materials.
However, our ability to compare diagnostic assays for emerging
Figure 4. Microarray analysis correctly identifies emerging viruses in clinical samples. The results of microarray analysis of WT-amplified
virus-positive clinical samples, using the SSI analysis method. Graphs show the signal mean for the probe intensities for each detected virus. The bar
across the graph demonstrates the signal threshold at the 99th percentile of the random control intensities. (A) Microarray analysis of a Dengue-
positive serum sample. (B) Microarray analysis of another Dengue-positive serum sample. (C) Microarray analysis of a WNV-positive urine sample. (D)
Microarray analysis of another WNV-positive urine sample.
doi:10.1371/journal.pone.0100813.g004
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viruses is limited due to the relatively small number of clinical
samples received at SSI containing these viruses.
Overall, the LLMDAv2 demonstrates high specificity and
sensitivity with few false positives. The majority of additional hits
found by the microarray data analysis are retroviruses normally
found in mammalian genomes (HERV, BEV, MDEV, MuLV and
MMTV). They are clinically irrelevant and most probably
originate from host or cell culture DNA. The BEV identified in
the Ebola virus, cowpox virus and monkeypox virus SN samples is
not surprising, since cross-hybridization of endogenous retrovirus-
es in African green monkey-derived Vero E6 cell cultures to the
BEV probes has been previously reported [26]. The MDEV,
MuLV and MMTV identified in the poliovirus sample are
consistent with the fact that PV is cultured in mouse-derived L20B
cells. In a few samples (Usutu virus, cowpox virus, monkeypox
virus, RVFV, Marburg virus, the WNV10-panel samples, one
clinical DENV sample, and one clinical WNV sample), additional
viruses were identified that predominantly belonged to the same
family or genus as the correct virus. All of them were determined
to be false positives by virus-specific PCR indicating a need to
improve the specificity of the probes or the analysis methods. Both
data analysis methods had difficulty in distinguishing between the
four different DENV subtypes (Table 1 and Figure 3B). This was
not surprising, since viral strain subtyping was not a goal of the
LLMDAv2 design [14]. Nevertheless, our work shows that
improvements to LLMDA probe specificity are needed to increase
its value for diagnosis and outbreak detection.
The CLiMax software is numerically intensive and requires a
large-memory LINUX server harbouring a library of probe-target
binding probabilities that are the basis for pathogen identification
[14,41]. The CLiMax analysis is sophisticated and powerful,
providing a user-friendly web interface to a database that keeps
track of requested analyses and their results. In addition to a list of
probable viruses, the CLiMax software can generate a target
sequence-probe alignment plot showing probe fluorescence
intensities together with the location of probe hits across each
viral genome detected. This can help to distinguish the presence of
whole viral genomes from non-specific probe hits and cross-
reactivity.
The analysis developed in-house at SSI processes microarray
feature intensities produced by the NimbleScan software within a
Microsoft Excel framework [19]. While the CLiMax analysis is
designed for broad-spectrum detection of all microbial targets
represented on the LLMDA, the Excel-based SSI analysis is more
focused toward identification of human-infecting viral pathogens.
The relative simplicity of the SSI analysis is attractive for a clinical
diagnostic environment, since it requires less costly computing
hardware, and provides a clearer diagnostic result for clinicians,
because clinically irrelevant non-human and non-zoonotic path-
ogens are excluded from the analysis. The CLiMax software is a
more sophisticated, precise tool for data analysis in a research
environment. Its ability to identify microbial pathogens from all
host species makes this analysis method ideal for analysis of special
cases such as detection of novel zoonotic viruses and research
purposes.
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